Updated just now · Live
Merck & Co., Inc. operates as a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. Keytruda is its leading oncology treatment.
Merck & Co., Inc. operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for MRK.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). MRK Stock Intelligence Report. [stoxpulse.com/stocks/mrk]
Disclaimer: The information on this page about Merck & Co., Inc. (MRK) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Merck & Co., Inc..
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Earnings beat by 16%
Mar 31
Which dow jones stocks are moving on Tuesday?
1h ago
Investigational Once-Weekly Oral HIV Treatment Reg...
4h ago
StoxPulse AI results for MRK: Pulse Score 48.5/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$307.25B
P/E Ratio
17.2
EPS
$-1.72
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Jun 25
+7.7%
Sep 25
+13.1%
Dec 25
+3.0%
Mar 26
+16.0%
Beat estimates 4 of 4 quarters (100%)
Merck & Co., Inc. operates as a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. Keytruda is its leading oncology treatment.
Which dow jones stocks are moving on Tuesday?
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
Personalis: Tempus Bought The Best Part Of The Story
Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer
Merck (MRK) Declines More Than Market: Some Information for Investors
Stay informed with the top movers within the dow jones index on Monday.
Reading Between The Lines Of JNJ Stock's Latest Call